Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
BNGO
BIONANO GENOMICS, INC.
NASDAQ
$1.44
▼ DOWN 1.71% (-0.03)

KEY STATISTICS

Market Cap$16.81 M
52w High$2.23
52w Low$1.00
Dividend Yield—
Frequency—
P/E-0.48
Volume129.10K
Shares Out.11.47M

COMPANY

LEADERSHIP

Albert A. Luderer
CHIEF EXECUTIVE
Albert A. Luderer

COMPENSATION 2026

Salary$600,000
Stock Awards$40,901
Incentive Plan Pay$0
All Other Comp.$16,122
Total$989,677

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 21, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
96

PRICE TARGET

Target High$175.00
Target Low$1.00
Target Median$5.00
Target Consensus$46.50

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$8.44M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-01-27Reverse1:60
2023-08-07Reverse1:10

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
VXF
0.00%
82.4K
TYNE
3.47%
29.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
14.47%
HOLDERS
62
TOP 8 OF 62 · RANKED BY POSITION SIZE
Blackrock Inc.
607.7K sh
$412.01K
Gsa Capital Partners Llp
353.4K sh
$413K
Drw Securities, LLC
168.5K sh
$257.73K
Geode Capital Management, LLC
167.5K sh
$196.01K
Cetera Advisors LLC
146.8K sh
$162.96K
Vanguard Group Inc
82.3K sh
$125.93K
Carret Asset Management, LLC
70.0K sh
$81.9K
Ubs Group AG
63.9K sh
$109.23K

PRICE

$1.44 ▼ DOWN 1.71% (−$0.03)
OVERLAYS
$1.44$1.46$1.48$1.509:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM1.44

About Bionano Genomics, Inc.

https://bionano.com ↗

Bionano Genomics provides genome analysis software, optical genome mapping instruments, consumables, and genetic testing services to analyze structural variations and genetic disorders.

INDUSTRY

Medical - Instruments & Supplies

A PRODUCT BIONANO GENOMICS, INC. IS KNOWN FOR

Stratys System
Stratys System

The Stratys system by Bionano is an advanced high-throughput optical genome mapping instrument, generating up to four times more data than its predecessor, enabling detailed structural variation analysis for research and clinical applications.

COMPETITORS

COMPETITOR
ILMN COMPARE
PACB COMPARE
QGEN COMPARE
TMO COMPARE
TXG COMPARE

Bionano Genomics in 2025

SENTIMENT: − NEGATIVE
MARKET EVENT · JANUARY 2025

Bionano Genomics Executes 1-for-60 Reverse Stock Split to Maintain Nasdaq Listing

In a move to regain compliance with Nasdaq's minimum bid price requirement, Bionano Genomics implemented a 1-for-60 reverse stock split. This corporate action, effective January 24, 2025, significantly consolidated the number of outstanding shares and increased the per-share trading price, putting the company in the spotlight due to the market's often negative perception of such measures as a sign of underlying distress.

BUSINESS MODEL · Q1 2025 · IN PROGRESS

Bionano Genomics Pivots to a Consumables-Driven Recurring Revenue Model in 2025

In 2025, Bionano Genomics executed a significant strategic shift away from a capital-intensive instrument sales model to a high-margin, recurring revenue structure focused on consumables and software. This intentional pivot aims to stabilize financials and create a more predictable revenue stream by capitalizing on the growing utilization of its installed base of Optical Genome Mapping (OGM) systems.

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
XTLB$1.99COMPARE
KTTA$0.45COMPARE
QNRX$4.33COMPARE
NDRA$5.80COMPARE

INSIDER TRADES

★
DIRECTOR, OFFICER: INTERIM CHIEF EXECUTIVE
Luderer Albert
Purchase · 4.0K shares
2026-09-04
★
DIRECTOR, OFFICER: INTERIM CHIEF EXECUTIVE
Luderer Albert
Purchase · 4.0K shares
2026-08-21
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hastie Alex Reid
Purchase · 54.0K shares
2026-08-03
★
OFFICER: CHIEF OPERATING OFFICER
OLDAKOWSKI MARK
Purchase · 15.0K shares
2026-08-03